Ex-Novartis Exec Rahman To Steer Clinical Sciences At Glenmark
Dr. Mahboob Rahman, a former Novartis therapeutic area head for immunology in global clinical development, joins Glenmark at a key juncture as the Indian firm advances several key R&D assets including in immuno-oncology. “Portfolio prioritization” and bringing in the right talent rank high on Rahman’s immediate agenda, while a “fast-paced” environment appears to be among the key draws for his move.
You may also be interested in...
Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.